Expertise in
16
conditions

Dr. Meenakshi C. Patel

Internal Medicine
6611 Clyo Rd Ste E, 
Centerville, OH 
Accepting New Patients
Expertise in
16
conditions
6611 Clyo Rd Ste E, 
Centerville, OH 

Overview

Meenakshi Patel is a primary care provider, practicing in Internal Medicine in Centerville, Ohio.

Dr. Patel is highly rated in 16 conditions, according to our data. Her clinical expertise encompasses Alzheimer's Disease, Hypertensive Heart Disease, Enlarged Liver, and Pediatric Myocarditis.

She is actively involved in clinical research, co-authoring 6 peer reviewed articles and participating in 8 clinical trials. Dr. Patel is currently accepting new patients.

Specialties

Internal Medicine

Licenses

Geriatric Medicine in OH

Hospital Affiliations

Miami Valley Hospital
Kettering Health Main Campus
Kettering Health Dayton

Languages Spoken

English
Hindi
Marathi

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Buckeye Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthPartners
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medical Health
  • HMO
  • PPO
Medical Mutual
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

Valley Medical Primary Care
6611 Clyo Rd Ste E, Centerville, OH 45459

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: August 26, 2026
Intervention Type: Drug
Study Drug: Donanemab
Study Phase: Phase 3
A Phase 3, Randomized, Placebo-controlled, Observer-blind, Multi-country Study to Demonstrate the Efficacy of a Single Dose and Annual Revaccination Doses of GSK's RSVPreF3 OA Investigational Vaccine in Adults Aged 60 Years and Above
A Phase 3, Randomized, Placebo-controlled, Observer-blind, Multi-country Study to Demonstrate the Efficacy of a Single Dose and Annual Revaccination Doses of GSK's RSVPreF3 OA Investigational Vaccine in Adults Aged 60 Years and Above
Enrollment Status: Completed
Publish Date: July 31, 2025
Intervention Type: Biological
Study Drug: RSVPreF3
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness
A Randomized, Double-blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness
Enrollment Status: Completed
Publish Date: April 11, 2024
Intervention Type: Drug
Study Drugs: Bamlanivimab, Etesevimab
Study Phase: Phase 2/Phase 3
A Phase 2a Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of SUVN-502 in Subjects With Moderate Alzheimer's Disease Currently Treated With Donepezil Hydrochloride and Memantine Hydrochloride
A Phase 2a Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of SUVN-502 in Subjects With Moderate Alzheimer's Disease Currently Treated With Donepezil Hydrochloride and Memantine Hydrochloride
Enrollment Status: Completed
Publish Date: June 09, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate COVID-19 Illness (BLAZE-4)
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate COVID-19 Illness (BLAZE-4)
Enrollment Status: Completed
Publish Date: July 01, 2022
Intervention Type: Drug
Study Drugs: Bamlanivimab, Etesevimab, LY3853113 Anti-COVID-19 Antibody, VIR-7831 Anti-COVID-19 Antibody
Study Phase: Phase 2
Effect of LY3202626 on Alzheimer's Disease Progression as Measured by Cerebral ¹⁸F-AV-1451 Tau-PET in Mild Alzheimer's Disease Dementia
Effect of LY3202626 on Alzheimer's Disease Progression as Measured by Cerebral ¹⁸F-AV-1451 Tau-PET in Mild Alzheimer's Disease Dementia
Enrollment Status: Terminated
Publish Date: April 19, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Clinico-Pathological Study of the Correspondence Between 18F-AV-1451 PET Imaging and Post-Mortem Assessment of Tau Pathology
A Clinico-Pathological Study of the Correspondence Between 18F-AV-1451 PET Imaging and Post-Mortem Assessment of Tau Pathology
Enrollment Status: Completed
Publish Date: September 07, 2020
Intervention Type: Drug, Procedure
Study Phase: Phase 3
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Enrollment Status: Terminated
Publish Date: December 03, 2019
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
View 7 Less Clinical Trials

6 Total Publications

INSULIN GLARGINE 300 U/ML IS ASSOCIATED WITH LESS WEIGHT GAIN WHILE MAINTAINING GLYCEMIC CONTROL AND LOW RISK OF HYPOGLYCEMIA COMPARED WITH INSULIN GLARGINE 100 U/ML IN AN AGING POPULATION WITH TYPE 2 DIABETES.
INSULIN GLARGINE 300 U/ML IS ASSOCIATED WITH LESS WEIGHT GAIN WHILE MAINTAINING GLYCEMIC CONTROL AND LOW RISK OF HYPOGLYCEMIA COMPARED WITH INSULIN GLARGINE 100 U/ML IN AN AGING POPULATION WITH TYPE 2 DIABETES.
Journal: Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
Published: November 07, 2017
Similar Doctors
Expertise in
13
conditions
Dr. David S. Vitale
Internal Medicine
Expertise in
13
conditions
Dr. David S. Vitale
Internal Medicine

Office

3333 Burnet Ave, 
Cincinnati, OH 
 (40.3 miles away)
513-636-4415
Languages Spoken:
English
See accepted insurances
Accepting New Patients

David Vitale is a primary care provider, practicing in Internal Medicine in Cincinnati, Ohio. Dr. Vitale is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Childhood Pancreatitis, Hereditary Pancreatitis, Acute Pancreatitis, Islet Cell Transplantation, and Pancreatectomy. Dr. Vitale is currently accepting new patients.

Expertise in
6
conditions
Dr. Bruce C. Trapnell
Internal Medicine
Expertise in
6
conditions
Dr. Bruce C. Trapnell
Internal Medicine

Office

2830 Victory Pkwy Ste 310, 
Cincinnati, OH 
 (40.7 miles away)
513-475-7521
Languages Spoken:
English, French, Japanese, Mandarin, Spanish
See accepted insurances
Accepting New Patients

Bruce Trapnell is a primary care provider, practicing in Internal Medicine in Cincinnati, Ohio. Dr. Trapnell is highly rated in 6 conditions, according to our data. His clinical expertise encompasses Pulmonary Alveolar Proteinosis, Alpha-1 Antitrypsin Deficiency (AATD), Lymphangioleiomyomatosis, and Cystic Fibrosis. Dr. Trapnell is currently accepting new patients.

Expertise in
32
conditions
Dr. John E. Mauer
Internal Medicine
Expertise in
32
conditions
Dr. John E. Mauer
Internal Medicine

Premier Integrated Medical Assoc. LTD

540 Lincoln Park Blvd Ste 200, 
Dayton, OH 
 (2.7 miles away)
937-293-1117
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

John Mauer is a primary care provider, practicing in Internal Medicine in Dayton, Ohio. Dr. Mauer is highly rated in 32 conditions, according to our data. His clinical expertise encompasses High Cholesterol, Glucose Phosphate Isomerase Deficiency, Glucose-Galactose Malabsorption Deficiency, and Congenital Sucrase-Isomaltase Deficiency. Dr. Mauer is currently accepting new patients.

Frequently Asked Questions about Dr. Meenakshi C. Patel

How do I make an appointment with Dr. Meenakshi C. Patel?

You can book an appointment with Dr. Meenakshi C. Patel by calling their office at 937-208-8282. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Meenakshi C. Patel a top-rated expert for Alzheimer's Disease?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Meenakshi C. Patel is classified as an Distinguished expert for Alzheimer's Disease, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Meenakshi C. Patel specialize in?

While Dr. Meenakshi C. Patel is a Internal Medicine, they have specific expertise in Alzheimer's Disease, Hypertensive Heart Disease, and Enlarged Liver. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. Meenakshi C. Patel participate in research or clinical trials?

Yes. Dr. Meenakshi C. Patel has published 6 articles and abstracts on conditions like Alzheimer's Disease. You can view a list of Dr. Meenakshi C. Patel's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Meenakshi C. Patel accept my insurance?

Dr. Meenakshi C. Patel accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 937-208-8282 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Patel's expertise for a condition
ConditionClose
    View All 14 Advanced Conditions
    View All 92 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile